Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Net Income (2016 - 2025)

Viking Therapeutics (VKTX) has disclosed Net Income for 12 consecutive years, with -$157.7 million as the latest value for Q4 2025.

  • Quarterly Net Income fell 345.56% to -$157.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$359.6 million through Dec 2025, down 227.0% year-over-year, with the annual reading at -$359.6 million for FY2025, 227.0% down from the prior year.
  • Net Income hit -$157.7 million in Q4 2025 for Viking Therapeutics, down from -$90.8 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of -$12.4 million in Q4 2021 to a low of -$157.7 million in Q4 2025.
  • Historically, Net Income has averaged -$34.0 million across 5 years, with a median of -$20.9 million in 2022.
  • Biggest five-year swings in Net Income: dropped 10.44% in 2023 and later crashed 345.56% in 2025.
  • Year by year, Net Income stood at -$12.4 million in 2021, then crashed by 58.29% to -$19.6 million in 2022, then decreased by 25.72% to -$24.6 million in 2023, then crashed by 44.0% to -$35.4 million in 2024, then tumbled by 345.56% to -$157.7 million in 2025.
  • Business Quant data shows Net Income for VKTX at -$157.7 million in Q4 2025, -$90.8 million in Q3 2025, and -$65.5 million in Q2 2025.